All In Biotech

Drug Trial Radar · NCT02465060

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Molecular Analysis for Therapy Choice (MATCH)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

6,452

Planned (sponsor's estimate)

Start

Aug 17, 2015

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
NIH
First posted
Jun 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Screening
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

Conditions

  • Advanced Lymphoma
  • Advanced Malignant Solid Neoplasm
  • Bladder Carcinoma
  • Breast Carcinoma
  • Cervical Carcinoma
  • Colon Carcinoma
  • Colorectal Carcinoma
  • Endometrial Carcinoma
  • Esophageal Carcinoma
  • Exocrine Pancreas Carcinoma
  • Gastric Carcinoma
  • Glioma
  • Head and Neck Carcinoma
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Kidney Carcinoma
  • Liver Carcinoma
  • Lung Carcinoma
  • Lymphoma
  • Malignant Uterine Corpus Neoplasm
  • Malignant Uterine Neoplasm
  • Melanoma
  • Multiple Myeloma
  • Ovarian Carcinoma
  • Prostate Carcinoma
  • Rectal Carcinoma
  • Recurrent Bladder Carcinoma
  • Recurrent Breast Carcinoma
  • Recurrent Cervical Carcinoma
  • Recurrent Colon Carcinoma
  • Recurrent Colorectal Carcinoma
  • Recurrent Esophageal Carcinoma
  • Recurrent Gastric Carcinoma
  • Recurrent Glioma
  • Recurrent Head and Neck Carcinoma
  • Recurrent Liver Carcinoma
  • Recurrent Lung Carcinoma
  • Recurrent Lymphoma
  • Recurrent Malignant Solid Neoplasm
  • Recurrent Malignant Uterine Corpus Neoplasm
  • Recurrent Melanoma
  • Recurrent Multiple Myeloma
  • Recurrent Ovarian Carcinoma
  • Recurrent Pancreatic Carcinoma
  • Recurrent Prostate Carcinoma
  • Recurrent Rectal Carcinoma
  • Recurrent Skin Carcinoma
  • Recurrent Thyroid Gland Carcinoma
  • Refractory Lymphoma
  • Refractory Malignant Solid Neoplasm
  • Refractory Multiple Myeloma
  • Skin Carcinoma
  • Thyroid Gland Carcinoma

Interventions

  • AdavosertibDrug

    Given PO

  • AfatinibDrug

    Given PO

  • Afatinib DimaleateDrug

    Given PO

  • BinimetinibDrug

    Given PO

  • Biopsy ProcedureProcedure

    Undergo tumor biopsy

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • CapivasertibDrug

    Given PO

  • Computed TomographyProcedure

    Undergo computed tomography (CT)

  • CopanlisibDrug

    Given IV

  • Copanlisib HydrochlorideDrug

    Given IV

  • CrizotinibDrug

    Given PO

  • Cytology Specimen Collection ProcedureOther

    Optional correlative studies

  • DabrafenibDrug

    Given PO

  • Dabrafenib MesylateDrug

    Given PO

  • DasatinibDrug

    Given PO

  • DefactinibDrug

    Given PO

  • Defactinib HydrochlorideDrug

    Given PO

  • Echocardiography TestProcedure

    Undergo echocardiography (ECHO)

  • ErdafitinibDrug

    Given PO

  • FexagratinibDrug

    Given PO

  • IpatasertibDrug

    Given PO

  • Laboratory Biomarker AnalysisOther

    Undergo molecular analysis

  • LarotrectinibDrug

    Given PO

  • Larotrectinib SulfateDrug

    Given PO

  • Magnetic Resonance ImagingProcedure

    Undergo magnetic resonance imaging (MRI)

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • NivolumabBiological

    Given IV

  • OsimertinibDrug

    Given PO

  • PalbociclibDrug

    Given PO

  • PertuzumabBiological

    Given IV

  • PI3K-beta Inhibitor GSK2636771Drug

    Given PO

  • Radiologic ExaminationProcedure

    Undergo radiologic evaluation

  • Radionuclide ImagingProcedure

    Undergo nuclear study

  • RelatlimabBiological

    Given IV

  • SapanisertibDrug

    Given PO

  • Sunitinib MalateDrug

    Given PO

  • TaselisibDrug

    Given PO

  • TrametinibDrug

    Given PO

  • TrastuzumabBiological

    Given IV

  • Trastuzumab EmtansineBiological

    Given IV

  • UlixertinibDrug

    Give PO

  • VismodegibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Up to 3 years

Locations

1,410 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Thomas Hospital

    Fairhope, Alabama

  • Mobile Infirmary Medical Center

    Mobile, Alabama

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Regional Hospital

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • CTCA at Western Regional Medical Center

    Goodyear, Arizona

  • Kingman Regional Medical Center

    Kingman, Arizona

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona

  • Saint Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • Community Cancer Institute

    Clovis, California

  • University Oncology Associates

    Clovis, California

Showing 40 of 1,410 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.